Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a sell rating to a hold rating in a report published on Friday morning, BidAskClub reports.

Several other brokerages have also issued reports on ESPR. Bank of America upgraded shares of Esperion Therapeutics from an underperform rating to a neutral rating in a research note on Monday, May 6th. Stifel Nicolaus reiterated a buy rating on shares of Esperion Therapeutics in a research note on Thursday, June 13th. Citigroup set a $73.00 price target on shares of Esperion Therapeutics and gave the company a buy rating in a research note on Tuesday, May 28th. ValuEngine downgraded shares of WideOpenWest from a hold rating to a sell rating in a research report on Friday, June 28th. Finally, Credit Suisse Group set a €50.00 ($58.14) price objective on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Monday, May 6th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Esperion Therapeutics presently has an average rating of Buy and an average target price of $74.45.

Shares of ESPR stock opened at $45.61 on Friday. Esperion Therapeutics has a 1 year low of $36.06 and a 1 year high of $60.99. The company has a fifty day simple moving average of $48.58. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -6.05 and a beta of 1.73.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $2.43. The business had revenue of $145.42 million during the quarter, compared to analyst estimates of $69.35 million. During the same quarter in the previous year, the firm posted ($1.73) earnings per share. As a group, equities research analysts predict that Esperion Therapeutics will post -2.65 earnings per share for the current year.

In other news, CEO Timothy M. Mayleben acquired 5,000 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was bought at an average price of $46.00 per share, with a total value of $230,000.00. Following the transaction, the chief executive officer now directly owns 66,163 shares in the company, valued at approximately $3,043,498. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Advisor Group Inc. boosted its holdings in shares of Esperion Therapeutics by 44.4% during the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 291 shares during the period. Parallel Advisors LLC bought a new stake in shares of Esperion Therapeutics during the 1st quarter worth about $80,000. Marshall Wace North America L.P. bought a new stake in shares of Esperion Therapeutics during the 1st quarter worth about $164,000. Marshall Wace LLP bought a new stake in shares of Esperion Therapeutics during the 1st quarter worth about $186,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of Esperion Therapeutics by 288.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,045 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,745 shares during the period.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: What is the return on assets (ROA) ratio?

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Anticipate Compass Diversified Holdings  to Post $0.40 Earnings Per Share
Zacks: Analysts Anticipate Compass Diversified Holdings to Post $0.40 Earnings Per Share
Private Advisor Group LLC Sells 10,389 Shares of Invesco BuyBack Achievers ETF
Private Advisor Group LLC Sells 10,389 Shares of Invesco BuyBack Achievers ETF
Private Advisor Group LLC Has $3.91 Million Stake in Schwab U.S. Mid-Cap ETF
Private Advisor Group LLC Has $3.91 Million Stake in Schwab U.S. Mid-Cap ETF
Analysts’ Recent Ratings Changes for Power Integrations
Analysts’ Recent Ratings Changes for Power Integrations
Mondelez International Inc  Shares Sold by Private Advisor Group LLC
Mondelez International Inc Shares Sold by Private Advisor Group LLC
Prudential Financial Inc. Trims Position in AerCap Holdings
Prudential Financial Inc. Trims Position in AerCap Holdings


 
© 2006-2019 Zolmax.